1. Quad-class exposed/refractory myeloma is associated with short survival.
- Author
-
Piron B, Costes-Tertrais D, Gastinne T, Fourmont AM, Dubruille V, Blin N, Moreau P, Touzeau C, and Tessoulin B
- Subjects
- Humans, Retrospective Studies, Prognosis, B-Cell Maturation Antigen, Immunotherapy, Adoptive, Multiple Myeloma drug therapy, Immunoconjugates, Antibodies, Bispecific therapeutic use
- Abstract
Very scarce data exist about outcomes of relapsed multiple myeloma patients who have failed proteasome inhibitor, immunomodulatory drug, anti-CD38 monoclonal antibody and therapies targeting B-cell maturation antigen (BCMA) (Quad-class exposed [QCE]). In this retrospective single-centre study, we determined progression-free survival (PFS) and overall survival (OS) from anti-BCMA failure in 45 QCE patients. Seven (16%) patients received antibody-drug conjugate, 20 (44%) bispecific antibodies and 18 (40%) CAR-T cell. Thirty patients (67%) received ≥1 subsequent line of treatment. PFS was 4.4 months (95% CI = 2.4-12.5) and OS 6.3 months (95% CI = 3.9-14.4). Having an adverse prognosis, QCE myeloma patients remain an unmet medical need., (© 2023 British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF